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Abstract  
Tuberculosis (TB) is an infectious lung disease that is a major cause of mortality, causing an 
estimated 1.7 million deaths globally per year. The current prophylactic vaccine used against 
TB, bacille Calmette Guérin (BCG), fails to reliably protect against pulmonary TB in adults. A 
more efficacious vaccine to protect against TB is urgently required. The recent discovery of a 
new immune cell subset, the innate lymphoid cells (ILCs) have provided a potential target for 
vaccine development. Previous work by the Kirman lab revealed an increase in the number of 
ILCs in murine lungs at 4 weeks post-vaccination with i.n. BCG. My project used a mouse 
model to determine how early after BCG vaccination ILCs proliferate, and whether ILCs 
proliferate within the lungs or traffic to the lungs after expanding elsewhere. Understanding 
the anatomical site of ILC proliferation following BCG vaccination will provide insight into the 
role of ILCs in the immune response to the BCG vaccine, and will help inform the best route 
of vaccine delivery. It was hypothesised that ILCs would divide within the lung, as lung-
resident ILC populations have been documented.   
 
Two experimental approaches were used to test the hypothesis that ILCs proliferate in the 
lungs following BCG vaccination. The first method was an in-vivo dual labelling system which 
used intranasal administration of the fluorescent dye carboxyfluorescein diacetate 
succinimidyl ester (CFSE) to label cells of the lungs, and the thymidine analogue 
bromodeoxyuridine (BrdU) to label all proliferating cells in the mouse. Using flow cytometry, 
ILC subsets were then analysed for the presence of CFSE and BrdU, indicating whether 
proliferation had occurred within the lungs. The second method utilised the 
immunomodulatory drug FTY720 to block lymphocyte egress from secondary lymphoid tissue 
to see if this altered the numbers of proliferating ILCs in the lungs, thereby indicating whether 
or not ILCs proliferate locally within the lungs.  
 
Both approaches showed BCG vaccination induced ILC proliferation within the lungs, which 
was consistently elevated between 1.5 and 4 weeks post-vaccination.  These important 
findings have laid the foundation for further research into the role of ILCs in anti-
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1 Introduction  
1.1 Introduction to TB  
Tuberculosis (TB) is an infectious pulmonary disease1 caused by the bacterial pathogen 
Mycobacterium tuberculosis (Mtb).2 While the importance of the adaptive immune response 
in fighting TB infection has been well-established, more recently the innate immune response 
is also thought to be important. An increasing area of interest is the potential role of a newly 
discovered subset of immune cells, the innate lymphoid cells (ILCs) in anti-mycobacterial 
immunity. However, the function of ILCs in the lung is currently poorly understood, and little 
is known about the involvement of these cells in fighting TB infection.  
 
1.1.1 Epidemiology of TB 
TB remains a major cause of mortality on a global scale, causing an estimated 1.7 million 
deaths per year, and one third of the world’s population is infected with Mtb.3 The burden of 
this disease exhibits an uneven global distribution which generally correlates to the 
developed status of a country, particularly in terms of healthcare resources. In that regard, 
developing countries experience disproportionately high rates of mortality and morbidity 
caused by TB infection, with over 95% of deaths from TB occurring in low-and middle-income 
countries.4  
 
1.1.2 Control of TB  
Drug-susceptible TB is treatable with a six-month course of four first-line antimicrobial drugs: 
isoniazid, rifampicin, ethambutol, and pyrazinamide.4 When properly adhered to, this 
treatment regimen is effective in curing most TB cases. However, drug resistance can arise 
through incorrect prescription, inappropriate use of antimicrobials, or through premature 
cessation of treatment. The emergence of multidrug-resistant TB, a form of TB in which the 
bacteria are unresponsive to isoniazid and rifampicin, and extensively drug-resistant TB, 
where the bacteria also develop resistance to fluoroquinolones and at least one of three 
injectable second-line drugs (amikacin, kanamycin, or capreomycin) makes treatment 
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challenging.5 An effective prophylactic vaccine is therefore crucial in reducing the global 
burden of TB.  
 
1.2 Current vaccination against TB  
The current prophylactic vaccine used against TB is Bacille Calmette Guérin (BCG), a live 
attenuated form of Mycobacterium bovis,6 developed by French bacteriologists Albert 
Calmette and Camille Guérin in the early 1900s. BCG has been in use since 1921, and has 
saved many lives during this time.  
 
The BCG vaccine has been shown to confer consistent protection against TB meningitis and 
disseminated TB in children, however the efficacy of this vaccine in protecting against 
pulmonary disease in adolescents and adults has proven to be highly variable.7 A 1990 review 
study analysing the efficacy of BCG highlighted this extreme variability, showing that efficacy 
rates ranged from 0% in South India to 80% in the United Kingdom.8 This variation may be 
attributable to genetic, environmental, and socioeconomic factors that differ across the 
globe, and may also be associated with the genetic diversity of BCG strains used between 
different laboratories.9 The conditions under which BCG is manufactured has differed 
between laboratories since its origin in 1921, and microbiological characteristics of the 
different strains are distinct from one another.10 The diversity of BCG may contribute to the 
global variance in BCG-mediated protection.   
 
The large variance in the efficacy of BCG against pulmonary disease is problematic, as 
pulmonary TB is the most prevalent form of active disease, accounting for approximately 90% 
of cases.11 In order to control the global TB epidemic, a prophylactic vaccine that significantly 
reduces the incidence of pulmonary TB in both children and adults in a consistent manner is 
necessary. Research that provides further insight into the immune response against Mtb is 
crucial in order to progress the development of a more efficacious vaccine. 
 
1.3 Immunopathology of TB and formation of the granuloma  
The respiratory tract serves as the portal of entry for contaminated aerosols containing Mtb 
bacilli, after which they infect various innate immune cells in the lung, including alveolar 
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macrophages, type 2 pneumocytes, dendritic cells (DCs), monocytes and neutrophils.12 
Uptake of Mtb bacilli by alveolar macrophages leads to triggering of innate immune signalling 
cascades, which promote the further recruitment of immune cells including more 
macrophages, dendritic cells, and lymphocytes to the primary site of infection. Important pro-
inflammatory cytokines involved in this process include interferon-gamma (IFN-) and tumour 
necrosis factor-alpha (TNF-). This immune cell recruitment is followed by the formation of a 
highly organised structure called a granuloma, with a core of infected macrophages that 
become surrounded by CD4+ and CD8+ T lymphocytes as the adaptive immune response 
ensues. While macrophages generally kill phagocytosed bacteria, during established Mtb 
infection, phagocytic macrophages in alveolar spaces of the lung host mycobacteria without 
killing the bacilli.  
 
The granuloma initially aids in containing infection; however, it simultaneously provides a 
survival niche where some bacilli can persist in a latent form for prolonged periods of time.12 
In a small number of cases (5-10%), particularly in immunocompromised individuals such as 
those infected with HIV, the bacilli reactivate to cause active TB disease.13 Reactivation 
induces the death of infected cells, causing subsequent disintegration of the granuloma which 
enables dissemination of Mtb throughout the respiratory tract.  
 
1.4 The immune response to TB  
1.4.1 The innate and adaptive components of the immune system  
The overall immune system comprises two main branches that interact with one another to 
function as a whole: the innate and the adaptive immune arms.  The innate immune system 
provides a rapid immune response upon infection, and is mediated by various innate cell 
types including DCs, neutrophils, and macrophages.14 Pathogen recognition occurs through 
the use of germline-encoded receptors in a non-specific manner. Conversely, the adaptive 
immune system, encompassing CD4+ and CD8+ T lymphocyte and B lymphocyte responses, 
is slower to commence but provides a highly specific response. During adaptive immunity, 
pathogen recognition is mediated by antigen-specific receptors that have undergone somatic 
gene rearrangement during lymphocyte development in the bone marrow (B cells) or thymus 
(T cells).   
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1.4.2  Innate immunity to TB infection  
DCs and macrophages encounter Mtb during the early stages of infection, detecting 
pathogen-associated molecular patterns through toll-like receptors.15 These cells engulf 
mycobacteria through phagocytosis, after which they process and present Mtb antigens to T 
cells through class I and II Major Histocompatibility Complex (MHC), effectively forming a 
connection between the innate and adaptive branches of the immune system.  
 
In addition to innate myeloid cells, natural killer (NK) cells, which are a type of innate lymphoid 
cell, are also thought to play an important role in anti-mycobacterial immunity, conferring 
protection through the production of IFN-.16 This cytokine is important in the activation of 
macrophages, and thereby enhances the killing of Mtb. Furthermore, NK cells exert cytotoxic 
function through the lysis of Mtb-infected macrophages.  
 
1.4.3 Subversion of host immune defences  
While ingestion of bacteria by innate phagocytes normally results in bacterial degradation, 
this is not always the case. Mtb is unusual in its ability to remain dormant in phagocytes, 
particularly alveolar macrophages, through the inhibition of phagolysosome maturation, 
enabling survival within the host environment.17 This unique intracellular survival strategy of 
Mtb can hinder therapeutic intervention, and consequently exacerbate the burden of disease.  
 
1.4.4 The adaptive immune response to TB  
Adaptive immunity to Mtb becomes evident 3-8 weeks following initial pathogen exposure, 
and is primarily mediated by CD4+ T cell populations.18 Activation and expansion of naïve 
CD4+ T cells occurs in the lymph nodes, where DCs present Mtb antigen on MHC-II, marking 
the initiation of Mtb-specific adaptive immunity. The effector CD4+ T cell response is 
characterised by high production of IFN-, as well as TNF and interleukin-2 (IL-2). T cell-
mediated immunity is considered to be superior in the control of TB, as Mtb is an intracellular 
pathogen.19 
 
While the primary goal of the adaptive immune system is to clear infection, the ability to 
recognise the pathogen and respond more rapidly and effectively upon subsequent 
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encounters is another key aspect of adaptive immunity. This phenomenon is referred to as 
immunological memory, and forms the basis of vaccine development.20 
 
1.4.5 Development of vaccines against Mtb  
The limited efficacy of the BCG vaccine against pulmonary disease and the escalating 
incidence of drug-resistant forms of TB21 highlight the urgent requirement for a more 
efficacious vaccine. There are currently 13 vaccine candidates under evaluation in phase I, II, 
and III clinical trials, which aim to prevent either infection, disease progression, or reactivation 
of latent TB infection.8  
 
To date, vaccine development against TB has been based on the induction of effector T cell 
responses. The BCG vaccine stimulates cytokine-producing CD4+ T cell responses, with IFN-, 
TNF, and IL-2 typically being the most common cytokines expressed.22 IFN--producing CD8+ 
T cells are also induced by BCG, but to a lesser extent than CD4+ T cells. However, the 
inefficacy of BCG in protecting against pulmonary TB raises the question of whether T cell-
mediated immunity confers sufficient protection, and highlights the current lack of 
knowledge as to what constitutes a protective anti-mycobacterial immune response.   
 
This lack of knowledge is further evidenced by the underwhelming results from various clinical 
trials assessing vaccine strategies against TB, such as those from a phase 2b trial measuring 
the safety and efficacy of a modified Vaccinia Ankara virus expressing the Mtb antigen 85A.23 
Efficacy was assessed in terms of both incident TB and Mtb infection. A CD4+ T cell response 
to Ag85 was detected, characterised by high production of IFN-, TNF-, and IL-2, and these 
responses were absent in the placebo control group. However, this vaccine-induced T cell 
response did not translate to increased protection against TB, as the vaccine failed to 
significantly reduce both TB incidence and Mtb infection.  
 
1.5 Innate Lymphoid Cells  
1.5.1 Introduction to Innate Lymphoid Cells  
Innate lymphoid cells (ILCs) are a recently discovered subset of immune cells that develop 
from the common lymphoid progenitor (CLP) in the bone marrow.24 They exhibit similar 
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phenotypes and functions to T cells.25 However, as ILCs are devoid of antigen-specific 
receptors characteristic of adaptive immune populations, the activation and expansion of 
these cells is driven by cytokines, or by other signals emanating from infected or injured 
tissue. ILCs respond to these stimuli by releasing signature cytokines of their lineage that help 
shape the developing immune response.  
 
 ILCs are able to respond rapidly to invading pathogens due to their strategic placement at 
mucosal surfaces. These cells have also been shown to be important in epithelial repair, tissue 
homeostasis, metabolism, and immune regulation,26 through the secretion of cytokines and 
reciprocal interactions with macrophages.27 While the presence of ILCs in the lung has been 
established, the role of these cells in this organ is poorly understood, especially with regard 
to TB.  
 
ILCs can be divided into three main subsets: group 1 ILCs, group 2 ILCs, and group 3 ILCs. 
Classification of ILCs into these distinct subsets can be based upon their expression of lineage-
specific genes, transcription factors, and signature cytokine profiles.28  
 
1.5.2  Group 1 ILCs  
ILC1 cells and NK cells are both categorised as group 1 ILCs on the basis of their responsiveness 
to pro-inflammatory cytokines interleukin (IL)-15, IL-12, and IL-18, and their secretion of IFN-
 and TNF once activated.29 However, while phenotypically similar in terms of cytokine 
production, ILC1s and NK cells are developmentally and transcriptionally distinct.30 
Phenotypic and functional characteristics of ILC1s, such as the production of IFN-, is 
regulated by the T-bet transcription factor. While T-bet can also be expressed by NK cells, it 
is expressed to a lesser extent than in other ILC1s and is not crucial for NK cell development. 
In addition to T-bet, NK cells express the transcription factor eomesodermin (Eomes). Group 
1 ILCs play an important role in mediating the immune response to various intracellular 
bacterial and parasitic infections.  
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1.5.3 Group 2 ILCs  
Group 2 ILCs mediate a Th2-like response, characterised by the production of cytokines IL-5, 
IL-6, IL-9, and IL-13.31 Epithelial-derived cytokines IL-33, IL-25, and thymic stromal 
lymphopoietin (TSLP) activate group 2 ILCs. The transcription factor GATA-binding protein 3 
(GATA-3) is an essential determinant of group 2 ILC development, as evidenced by the loss of 
critical ILC2 genes in GATA-3 knockout models in mature ILC2s.32 Group 2 ILCs are important 
in the immune response to helminth infection, and are also involved in wound healing and 
tissue repair. Furthermore, ILC2s play an important role in the initiation of an allergic immune 
response, however they have also been implicated in the exacerbation of airway 
inflammation during allergic asthma.26  
 
1.5.4 Group 3 ILCs 
A high degree of heterogeneity is observed within group 3 ILCs. These cells are primarily 
located in mucosal sites such as the intestinal mucosa, where they contribute to the 
maintenance of gut homeostasis and prevent the colonisation of invading pathogens.30 Group 
3 ILC3s preferentially express the master transcription factor RORt, which regulates many 
ILC3-specific genes, such as those encoding signature cytokines IL-17 and IL-22. While ILC3s 
are important in promoting gut homeostasis and protection against pathogens, a causative 
role for these cells has been observed in various intestinal inflammatory diseases.  
 
Group 3 ILCs can be further categorised into lymphoid-tissue-inducer (LTi) cells, which are 
important in the formation of lymph nodes and Peyer’s patches, and natural-cytotoxicity-
receptor-positive (NCR+) and NCR- ILC3s, which are important in anti-bacterial immune 
responses.33   
 
1.5.5 Origin and trafficking of ILCs  
The development of ILCs occurs initially in the fetal liver, and later in the adult bone marrow.34 
CLPs give to rise T and B lymphocytes of the adaptive immune system; however, ILCs are also 
derived from a particular CLP subset. Several transcription factors are required for the 
development of ILCs from CLPs. These include inhibitor of DNA binding 2 (Id2), nuclear factor 
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interleukin-3 regulated (NFIL3), and thymocyte selection-associated high-mobility group box 
protein (TOX). 
 
The factors underpinning the tissue-specific migration of ILCs and the trafficking mechanisms 
involved in this process are an active area of research. It has been shown that the trafficking 
of ILC1s and ILC3s into secondary lymphoid tissue is facilitated by expression of lymphoid 
homing receptors, and, in order to migrate to the intestine, these cells undergo a ‘switch’ 
from lymphoid to gut homing receptor expression.35 This switch is dependent upon mucosal 
DCs and retinoic acid (RA), a gut-specific tissue factor. In contrast, ILC2s migrate directly from 
the bone marrow to the intestine following intrinsic acquisition of gut homing receptors, 
independent of RA. Moreover, it has recently been shown that a particular subset of IL-25-
responsive “inflammatory” ILC2s (iILC2s) migrate from the intestinal lamina propria to various 
peripheral sites, including the lung, upon exposure to IL-25 or helminth infection, where they 
assist in tissue repair and anti-helminth immunity.36 
 
Therefore, while ILCs are typically considered to be tissue-resident, the movement of ILC 
subsets between various anatomical locations has been described.   
 
1.5.6 Maintenance of tissue-resident ILCs   
Gasteiger et al established a long-term parabiotic model to determine whether permanent 
retention of tissue-resident ILCs was achieved through the self-renewal of these cells, or via 
continual replacement by haematogenous precursors.37 Three months following the 
establishment of parabiosis, it was found that essentially all ILCs in both lymphoid and non-
lymphoid organs were of host origin. These findings suggest that ILC tissue residency in 
peripheral organs is maintained locally through the self-renewal of ILCs, with only minor 
contributions from haematogenous precursors or mature circulating ILCs. Furthermore, upon 
the induction of systemic autoimmunity, there was no apparent contribution of 
haematogenous cells to the ILC expansion that was occurring in lymphoid and non-lymphoid 
organs. The observed increase in ILCs therefore appeared to be a result of local proliferation 
within these tissues.  
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1.5.7 Plasticity of ILC subsets  
ILCs are typically classified into three distinct lineages with unique functional capacities; 
however, plasticity has been observed between these subsets. For example, GATA3 
expression occurs at varying levels in all ILC subsets, with the differing levels of expression 
correlating to its unique functions within different types of cells.38  
 
While master regulators are preferentially expressed in particular cell types, it has been 
shown that the expression of two or more transcriptional master regulators can occur within 
ILC subsets, thereby facilitating a certain degree of plasticity. For example, the coexpression 
of T-bet and RORt in some CCR6- ILC3 populations has been demonstrated.39 However, the 
mechanisms that allow for stable coexpression of these two master regulators, and whether 
the activation of a unique transcriptional programme is dependent on the presence of both 
master regulators, remains unknown. Moreover, it has been shown that the upregulation of 
T-bet in some CCR6- ILC3s results in a corresponding downregulation of RORt, causing these 
cells to become more ILC1-like, acquiring the ability produce IFN-. The plasticity of ILCs may 
also be attributed in part to the dynamicity of transcriptional regulator expression in these 
cells,40 and the different signals that regulate their function after generation and after 
inflammation.  
 
The tissue microenvironment under physiologic and various pathologic conditions has been 
shown to influence ILC plasticity and functional specialisation. A study by Nussbaum et al 
showed that the fate and function of Rorc fate map-positive (Rorcfm+) ILC subtypes was 
dependent upon the surrounding tissue-specific microenvironment.41  Phenotypic profiling 
revealed that Rorcfm+ ILCs residing in lymphoid tissue were phenotypically indicative of NK 
cells, expressing high levels of the NK cell markers NKp46, NK1.1, and CD49b. In contrast, 
intestinal tissue-resident Rorcfm+ ILCs were predominantly negative for NK1.1 and CD49b, with 
heterogeneous expression of NKp46. These tissue-specific expression patterns by ILCs of the 
same lineage are suggestive of microenvironment-driven phenotypic specialisation. 
Concordantly, this study found that the phenotype and lineage marker expression of Rorcfm+ 
ILCs following adoptive transfer into recipient mice correlated strongly to the local tissue 
environment which they encountered, rather than their origin. Furthermore, this study 
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reported the downregulation of RORt on tumour-suppressive Rorcfm+ ILCs, with a 
corresponding increase in T-bet expression.  
 
Therefore, ILCs are highly plastic cells with the ability to alter their phenotype to match the 
microenvironment.  
 
1.5.8 Disparities in tissue distribution of ILC subsets between mice and humans  
The tissue composition of ILCs has been shown to differ between mice and humans. For 
example, the most abundant ILC subset in the mouse lung is ILC2s, whereas ILC3s are the 
most abundant subset in the human lung, accounting for 60% of total ILCs in this tissue.26 
However, while the murine model does not precisely mirror humans in terms of ILC 
composition and distribution, it is still useful for hypothesis testing and generating theories 
and concepts that can later progress to studies in non-human primates and potentially in 
humans.  
 
1.5.9 Role of ILCs in infectious disease  
Several studies have brought to light the important roles of ILCs in the immune response to 
pathogenic microorganisms. Following pathogen invasion, ILCs become mobilised and 
activated to produce effector cytokines – these include IFN-, IL-5, IL-13, IL-17, and IL-22.42  
 
Both ILC1-derived IFN- and ILC3-derived IL-22 have been associated with protective 
immunity against colonic infection with Salmonella enterica serovar Typhimurium.30 IFN- 
helps enhance bacterial clearance, and IL-22 initiates a signalling cascade ultimately resulting 
in the secretion of antimicrobial peptides.  This IL-22-initiated pathway is also important in 
the early immune response to Citrobacter rodentium, an enteric pathogen and causative 
agent of colitis in mice. Further evidence for the importance of ILC3-derived IL-22 comes from 
the observation that enhanced bacterial invasion and intestinal inflammation occurs in IL-22-
deficient mice, rendering them highly susceptible to infection.43 
 
ILC3s are also important in the immune response against Candida albicans, as they appear to 
be an important source of IL-22 during infection with this fungus.44 IL-22 has been shown to 
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control fungal overgrowth and maintain epithelial integrity during the early stages of 
candidiasis.  
 
The immune response to helminth infection is mediated via interactions between ILC2s and 
the epithelium.45 ILC2-derived IL-13 is an important cytokine during infection with the mouse 
nematode Nippostrongylus brasiliensis, as it enhances macrophage activation, goblet cell 
development, and smooth muscle contractility, which all function to promote parasite 
expulsion. The secretion of IL-13 by ILC2s was illustrated through the inability of IL-13-/- ILC2s 
to induce worm expulsion, a defect which was rescued by the transference of wild-type ILC2s 
into IL-13-deficient mice.46 
 
The ability of NK cells to induce lysis of infected cells and rapidly produce IFN- make them an 
important subset in antiviral and antineoplastic immunity.47 A growing body of evidence 
supports the notion that NK cells play an important role in the immune response to Mtb. The 
production of IFN- and IL-22 by NK cells indicates the importance of this subset in anti-
mycobacterial immunity; IFN- activates macrophages and enhances their bactericidal 
function, and the protective role of IL-22 during Mtb infection has been observed.  
 
These important findings provide justification for the continuation of investigation into the 
role of ILCs in infectious disease, and potentially into the manipulation of these cells for 
vaccine development.  
 
1.6 Innate immune memory  
Immunological memory has been defined as the ability of the adaptive immune system to 
mount a more rapid and robust response upon re-exposure to a specific antigen, and has 
traditionally been considered a function of adaptive lymphocytes.48 However, the discovery 
that cells of the innate immune system, including monocytes, natural killer (NK) cells, and 
group 2 innate lymphoid cells (ILC2s) are able to mediate memory responses challenges this 
definition, and opens up exciting new possibilities for vaccine development in the prevention 




1.6.1  Initial observations of trained immunity  
Early observations that the innate immune system was capable of immunological memory 
arose from studies in plants and invertebrates, which are devoid of an adaptive immune 
system.50 Following initial pathogen recognition, plants acquire widespread resistance 
throughout their tissues that protect against re-infection, a process referred to as “systemic 
acquired resistance”.   
 
An example of trained immunity in an invertebrate came from a 2007 study using the insect 
Drosophila melanogaster, which relies entirely on its innate immune system for antimicrobial 
defence.51 This study showed that exposure to a sub-lethal dose of Streptococcus pneumoniae 
resulted in enhanced protection against subsequent challenge with S. pneumoniae at a dose 
that would otherwise be lethal. As Drosophila lacks adaptive immunity, these results 
suggested that innate immune mechanisms must be responsible for the heightened response 
upon re-challenge. Following these early observations of trained immunity in lower 
organisms, this concept become the subject of many experiments in higher animals, such as 
mammals.     
 
1.6.2 Trained immunity of monocytes  
In mammals, monocytes and macrophages have been shown to exhibit antigen non-specific 
memory responses following activation by -glucan, which leads to enhanced phagocytic 
function and cytokine production upon rechallenge with unrelated pathogens.52 These 
functional enhancements persisted for up to 4 weeks, and were able to mediate a more 
robust immune response upon subsequent infections. This memory-like property of 
macrophages has been shown to be associated with epigenetic alterations, resulting in the 
enhanced activation of inflammatory genes.51 
 
1.6.3  Memory of NK cells  
The long-lived, antigen-specific memory response capabilities of NK cells was first observed 
in a 2006 study by O’Leary et al., which used a murine model of hapten-induced contact 
hypersensitivity (CHS).53 Even in T cell- and B cell- deficient mice, significant CHS responses to 
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the specific haptens took place. NK cells were found to accumulate rapidly at the site of 
hapten rechallenge, and it was discovered that these cells were mediating the hapten-specific 
memory response in the absence of T and B lymphocytes.  
 
These important findings sparked interest in the field of research concerning NK cell memory, 
and this phenomenon has been further established through a number of subsequent studies. 
In addition to haptens, NK cell memory has also been observed in the context of infection 
with influenza virus,54 vaccinia virus,55 HIV-1,56 murine cytomegalovirus,57 as well as the 
bacterial pathogen Ehrlichia muris.58 
 
While NK cell memory has been studied primarily using a murine model, a 2015 study by 
Reeves et al. described the same phenomenon in rhesus macaques.59 This study assessed the 
long-term antigen-specific memory capabilities of NK cells following vacation. Five years post-
vaccination, it was found that splenic and hepatic NK cells efficiently lysed antigen-matched 
targets (vaccine antigen), but were unable to efficiently lyse non-vaccine antigen, thereby 
exhibiting robust, antigen-specific memory.   
 
1.6.4 Evidence of NK cell memory in the context of Mtb infection  
Evidence favouring the phenomenon of NK cell memory in response to Mtb was provided by 
a 2011 study,60 which analysed NK cells isolated from the pleural fluid of Mtb-infected 
patients. It was found that NK cells expressing the memory marker CD45RO exhibited 
enhanced IFN- production and cytotoxicity when restimulated, compared to NK cells lacking 
the CD45RO marker. Further evidence of NK cell memory to Mtb came from a 2016 study by 
Suliman et al., who set out to determine whether re-vaccination with BCG enhanced NK cell 
responses in South African participants latently infected with Mtb.61 The results showed that 
the frequencies of IFN--producing NK cells were substantially elevated 3 weeks after re-
vaccination, and still remained at high levels one year later. 
 
While NK cell memory in the context of TB has been observed in the studies mentioned above, 
the results from a study by Kawahara et al conferred evidence against this concept.62 NK cells 
isolated from the spleens of BCG-vaccinated mice, and NK cells from the spleens of naïve 
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control mice responded in an equivalent manner in terms of IFN- production when 
stimulated with BCG. In addition, purified NK cells that had been exposed to BCG and NK cells 
from naïve mice were also similar in their ability to increase the antibacterial capacity of BCG-
infected macrophages. These contradictory findings warrant further research in the area of 
NK cell memory, particularly in the context of TB.  
 
1.6.5 Memory of group 2 Innate Lymphoid cells 
The ability of ILC2s to acquire immunological memory properties has been recently 
established. Intranasal administration of allergens or recombinant IL-33 into naïve mice 
caused a substantial expansion of ILC2 numbers in the lung, and following resolution of 
inflammation, these ILC2s persisted for several months in higher numbers compared to those 
in naïve mice.63 Furthermore, when these allergen-experienced ILC2s were challenged with 
an unrelated antigen several months later, they provided a more robust response 
characterised by enhanced proliferation and cytokine production, compared to ILC2s in naïve 
mice.  
 
This exciting discovery provides justification to further pursue the concept of ILC memory.   
While immunological memory has been demonstrated in ILC2s, it remains to be answered 
whether ILC1s and ILC3s are capable of mediating memory responses.  
 
1.6.6 Relevance of NK cell memory in vaccine development  
The stimulation of NK cells in the lungs and the subsequent formation of memory-like 
populations may be an attractive target for vaccination against TB, especially since NK cell 
memory in the context of TB infection has been observed. However, the underlying 
mechanisms governing the memory capabilities of these cells requires further investigation, 
in order to broaden our understanding of how innate immune memory can be harnessed by 
vaccination. Additionally, there is a current lack of knowledge regarding the strength and 
longevity of innate immune memory, which is an important concept as an effective vaccine 
must induce a prolonged memory response.  
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1.7 Justification for further research  
While considerable progress has been made in the field of research concerning innate 
lymphoid cells, gaps in knowledge are still clearly evident, particularly regarding the role of 
these cells in fighting Mtb infection.  
 
Previous research conducted in the Kirman Laboratory at the University of Otago used a 
C57BL/6 murine model to show that the number of ILCs in the lungs and lymph nodes 
increased following intranasal vaccination with BCG Pasteur strain 1173P2, which was 
accompanied by significant production of IFN-.64 The number of ILCs in the lungs one week 
post-vaccination were not significantly elevated compared to naïve control mice, however, 
four weeks post-vaccination a significant increase in the numbers of ILC1s, ILC2s, and ILC3s 
was observed. Interestingly, this expansion was not accompanied by a corresponding increase 
in NK cells. By 12 weeks post-vaccination, ILC numbers had regressed and were again 
comparable to naïve control mice.  
 
Furthermore, it was found that mucosal BCG vaccination induced greater accumulation of 
ILCs and enhanced production of IFN- in the lungs and lymph nodes compared to the 
traditional intradermal or subcutaneous vaccination routes. However, it remains unknown 
whether this increase in ILC number is due to local proliferation within the lungs, or due to 
inward migration of these cells from elsewhere in the body.  
 
1.8 Project Aims 
The overall objective of this research project was to investigate the anatomical site of ILC 
proliferation following intranasal vaccination with BCG. In addition to the main aim of 
determining whether ILCs proliferate within the lungs following BCG exposure, the kinetics of 
ILC proliferation were also explored, in order to establish the time taken for ILC proliferation 
to be induced, and when the peak ILC response can be observed.  
 
A better understanding of where in the body ILCs proliferate following BCG vaccination will 
assist in characterising the role and importance of ILCs in anti-mycobacterial immunity, and 
contribute to the limited pool of knowledge of the innate immune response during TB 
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infection. Additionally, should ILCs be found to contribute to vaccine-mediated protection 
against TB, this study will aid in determining the best route of vaccine delivery. For example, 
if ILCs are found to proliferate primarily in the lungs, this would suggest intranasal vaccination 
to be the most suitable choice.  
 
On the basis of previous research documenting lung-resident ILC populations, it was 
hypothesised that the lungs will be the predominant site of ILC proliferation following 
intranasal vaccination with BCG. It was also hypothesised that peak ILC expansion will be 
observed at approximately four weeks post-vaccination, based on previous findings by the 











2 Materials and Methods  
2.1 Animals   
2.1.1 Mice  
Male C57BL/6 mice aged a minimum of six weeks were used in all experiments, and were age-
matched within experiments. These mice were bred and housed in individually ventilated 
cages under specific pathogen-free conditions at the University of Otago in Dunedin, New 
Zealand. Mice were kept under a 12-hour light/dark cycle, and food and water was available 
ad-libitum throughout the course of experiments. The number of animals required in each 
group to enable statistical significance for the FTY720 study was determined using a power 
calculation with preliminary data, with the aid of biostatistician.   
 
2.1.2 Animal ethics  
Approval was granted for all animal experiments used in this study by the University of Otago 
Animal Ethics Committee. These experiments were conducted in accordance with guidelines 
set by the Animal Welfare Act (1999) of New Zealand.  
 
2.2 Preparation of in-vivo administered reagents 
2.2.1 Preparation of BCG Pasteur   
Aliquots of previously generated Mycobacterium bovis BCG Pasteur (strain 1173P2) in 
cryotubes were thawed at room temperature for 15 minutes and vortexed.  Cryotubes were 
then sonicated for 15 seconds using a Bandelin Sonorex Ultrasonic Sonicator (Bandelin, Berlin, 
Germany) to agitate particles and mix the solution, and then rested for 15 seconds at 4C. 
Sonication and resting was repeated for a total of three rounds. The BCG was then diluted 
1:20 in PBS-Tween 80 to prevent clumping, vortexed immediately, and stored at 4C until use.  
 
2.2.2 CFSE preparation  
Vials of 500g Carboxyfluorescein succinimidyl ester (CFSE) (BD HorizonTM, San Jose, CA, USA) 
were thawed and diluted in PBS to a concentration of 8mM by adding 112.1L PBS to each 
thawed 500g vial. Vials were stored at 4C until use.  
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2.2.3 BrdU preparation  
Bromodeoxyuridine (BrdU) was provided in a BrdU Flow Kit (BD PharmingenTM, San Jose, CA, 
USA), at a concentration of 10mg/mL in PBS. Vials were thawed, vortexed, and stored at 4C 
until use.   
 
2.2.4 Preparation of FTY720-supplemented drinking water  
FTY720 (Sigma-Aldrich) was prepared initially as a 10X solution (20g/mL) in MilliQ-H2O then 
diluted 1:10 in MilliQ-H2O to achieve the final desired concentration of 2g/mL.   
 
2.3 Intranasal BCG vaccination  
Mice were anaesthetised with either isofluorane gas (Merial New Zealand Ltd., Auckland, 
New Zealand) or with an intraperitoneal (i.p.) injection of 87mg/kg ketamine and 2.6mg/kg 
xylazine (Phoenix Pharm Distributors Ltd., Auckland, New Zealand) prior to the intranasal (i.n.) 
administration of BCG Pasteur. Once adequately sedated, mice were positioned supine and 
40L of 105 CFU BCG was gently pipetted onto the nostrils of each mouse for inhalation. Mice 
were actively monitored until full consciousness and mobility was regained.  
 
2.4 In-vivo administration of CFSE and BrdU  
Mice were anaesthetised with an i.p. injection of 87mg/kg ketamine and 2.6mg/kg xylazine 
(Phoenix Pharm Distributors Ltd., Auckland, New Zealand) and administered 40L of 8mM 
CFSE through the i.n. route. Two hours following CFSE administration, mice were 
anaesthetised using isofluorane gas, and administered 40L of i.n. and 200L of i.p. BrdU at 
10mg/mL.   
 
2.5 Collection of peripheral blood samples   
Tail bleeding was conducted twice during the FTY720 experiment in order to confirm 
lymphopenia. Mice were placed in a Perspex restrainer and a size 11, straight-cut sterile 
surgical blade (Swann-Morton) was used to make a small incision into the tail vein. A small 
volume of peripheral blood (up to 200l) was collected using a micropipette and immediately 
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suspended in 1ml of Alsever’s solution in a microcentrifuge tube to prevent coagulation. 
Blood samples were stored at 4C until further processing. Flow cytometry was used to 
quantify the percentage of total lymphocytes, CD4+ T cells, and CD8+ T cells in the blood.  
 
2.6 Harvesting and processing of murine tissue  
2.6.1 Aseptic technique  
All handling of animals and their tissues was conducted aseptically in a class II biological safety 
cabinet.  
 
2.6.2 Mouse euthanasia and dissection  
Mice were culled by an i.p. injection of a lethal dose (150mg/kg) of Pentobarbitone 300 
(Pentobarbital sodium; National Veterinary Supplies Ltd., Palmerston North, New Zealand). 
Death was confirmed by the cessation of respiration and of the foot pedal reflex. The lungs 
were flushed via injection of 1.5mL sterile PBS into the left ventricle of the heart, and 
dissections were performed to remove the lungs and spleen from mice. These tissues were 
immediately placed into 2.5mL of incomplete IMDM (iIMDM) in wells and stored at 4C until 
processing.  
 
2.6.3 Processing of tissue into single-cell suspensions  
Lungs were transferred into 2.5mL of lung digest media and dissected into small 2-3 mm 
segments using sterile dissection scissors, followed by incubation at 37C with 5% CO2 for 60 
minutes to digest structural tissue. The lungs and spleens were then passed through a pre-
wetted 70m cell strainer using a 1mL syringe plunger, and the strainer was rinsed with 5mL 
of complete IMDM (cIMDM).  This process was repeated a second time, followed by 
centrifugation at 400x g for 8 minutes at 4C to obtain a pellet. The supernatant was discarded 
and the cell pellets were resuspended in 2mL of red blood cell lysis buffer (Sigma-Aldrich) for 
3 minutes at room temperature to lyse red blood cells. A volume of 8mL cIMDM was added 
to the cell suspensions, which were then passed through a 30m cell strainer and centrifuged 
at 400xg at 4C for 8 minutes to pellet the cells. The supernatant was decanted and the cells 
were resuspended in 5mL of cIMDM for enumeration using a haemocytometer.  
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2.6.4 Viable cell counting  
Cells were diluted 1:10 in 0.1% Trypan blue dye (Gibco, Life Technologies), and counted using 
a haemocytometer (Boeckel & Co. GmbH, Hamburg, Germany) under a light microscope at 
40X magnification. Trypan blue is unable to penetrate the intact cell membrane of live cells, 
and therefore selectively stains dead cells. Viable lymphocytes were counted as those which 
excluded the Trypan blue dye. The number of lymphocytes per mL was calculated by 
multiplying the average number of viable lymphocytes per quadrant by the dilution factor 
(10), and then multiplying this number by 104. The total lymphocyte count per organ was 
determined by multiplying the number of lymphocytes per mL by the total volume of the cell 
suspension.  
 
2.7 Cell stimulation with PMA and Ionomycin  
Fresh murine cells were seeded into wells in a 6-well plate at a concentration of 1 x 106 cells 
per mL in cIMDM. Phorbol 12-myristate 13-acetate (PMA) was added to wells at a 
concentration of either 5ng/mL or 10ng/mL, and ionomycin was added to wells at a 




2.8 In-vitro labelling of cells with CFSE  
To create a 1mM stock of CFSE, 896.9L of PBS was added to a thawed 500g vial of CFSE. A 
volume of 50L of the 1mM CFSE stock was added to a 5mL cell suspension in PBS, to achieve 
a concentration of 10M. Cells were vortexed immediately to ensure uniform distribution of 
CFSE, followed by incubation at 37C for 15 minutes. A volume of 15mL PBS was added to the 
cell suspension, and cells were pelleted by centrifugation at 40x g for 8 minutes at 4C. 
Supernatant was discarded, cells were resuspended in 2mL PBS, and transferred into FACS 
tubes to proceed with staining for flow cytometry.  
 
2.9 Cell staining for Flow Cytometry  
Immunofluorescent labelling of cells for flow cytometry was carried out in Falcon Round-
Bottom Polystyrene Tubes (Stemcell Technologies, Canada). Centrifugation following each 
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wash step was performed at 400x g for 4 minutes at 4C throughout the staining protocol. 
Cells were incubated at 4C and were shielded from light by wrapping in aluminium foil during 
each incubation step, unless otherwise specified.   
 
2.9.1 FMO and unstained controls  
To assist in the development of a gating strategy, Fluorescence Minus One (FMO) controls 
were created for each of the nine markers used to identify ILCs, by staining cells with all of 
the antibodies except for the one of interest. Cells from all mice except for the mouse which 
did not receive i.n. CFSE were pooled and equally divided to create the FMO samples. The 
CFSE FMO and the unstained control sample used cells from the mouse which did not receive 
i.n. CFSE. The unstained control sample was not stained with any antibodies.  
 
2.9.2 FcRI/II blockade, lineage staining, and viability staining 
For FcRI/II blockade, lineage staining, and viability staining, cells were stained in 250l per 
sample and 100l per FMO and unstained control. To prevent non-specific binding of 
antibodies to the Fc receptor FcRI/II expressed on the surface of immune cells, lymphocytes 
were blocked for murine FcRI/II with anti-CD32/16 (clone 2.4G2, produced in-house) 
monoclonal antibody, diluted 1:10 in fluorescence-activated cell sorting (FACS) buffer. Tubes 
were incubated for 15 minutes to neutralise Fc receptors, after which the tubes were washed 
with 1mL FACS buffer and centrifuged. The supernatant was decanted and the cells were 
resuspended in a biotinylated -lineage cocktail containing seven -lineage antibodies. Tubes 
were incubated for 15 minutes to primary stain lineage markers expressed on the cell surface. 
Cells were then washed with 1mL FACS buffer. Following centrifugation and expulsion of 
supernatant, cells were resuspended in viability dye, diluted to 1:1000 in PBS, in order to stain 
dead cells. Tubes were incubated for 15 minutes and then cells were washed with 1ml PBS, 
centrifuged, and the supernatant was discarded.  
 
2.9.3 Cell surface marker staining 
A master mix of FACS buffer containing antibodies against cell surface markers at dilutions 
determined by previous titrations was compiled. Cells in sample and intracellular FMO tubes 
were resuspended in surface antibody master mix in a volume of 250L and 100L, 
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respectively. Unstained cells were resuspended in 100L FACS buffer. Tubes were incubated 
for 30 minutes to stain cell surface markers, and then washed with 1mL FACS buffer. Cells 
were pelleted via centrifugation and supernatant was discarded, followed by staining of the 
cells with antibodies specific for intranuclear markers.  
 
2.9.4 Intranuclear marker staining 
A transcription Factor Buffer set (BD PharmingenTM) was used to preserve cell morphology, 
fix cellular proteins, and permeabilise cells to facilitate subsequent immunofluorescent 
staining of the intranuclear transcription factors T-bet, Rort, and Eomes. DNase was used to 
separate DNA, thereby enabling the immunofluorescent staining of BrdU that had been 
incorporated into cells undergoing DNA synthesis. The intranuclear staining protocol was 
adapted from the BD PharmingenTM Transcription Factor Buffer Set Technical Data Sheet.  
 
Concentrated Fixation/Permeabilisation buffer was diluted at a ratio of 1:4 in transcription 
factor diluent buffer, and cells were resuspended in 0.5mL of this per tube. This was followed 
by a 45-minute incubation period with rocking motion. Tubes were then washed twice with 
0.5mL of 1x Perm/Wash buffer, which had been diluted 1:5 in MilliQ-H2O. For the in-vivo dual 
labelling experiment, cells were treated with DNase using a protocol adapted from the BD 
PharmingenTM BrdU Flow Kit Instruction Manual. Cells were resuspended in 250L of diluted 
DNase (300g/mL) per sample and 100L per FMO, and were incubated at 37C with 5% CO2 
for one hour. Cells were then washed in 1.0mL of 1x Perm/Wash buffer, tubes were 
centrifuged, and supernatant was discarded. For the FTY720 experiment the DNase step of 
the protocol was omitted, as Ki-67 was used in place of BrdU as a marker of proliferation. 
Cells were resuspended in 400L per sample and 100L per FMO of intracellular master mix 
containing antibodies against the intracellular markers of interest, at dilutions determined by 
previous titrations, and incubated for 45 minutes with rocking motion. Cells were then 
washed twice with 500L of 1x Perm/Wash buffer and resuspended in 200L formalin 
solution (4% w/v formaldehyde; Sigma-Aldrich) to final-fix cells and BCG. Cells were incubated 
at room temperature for 15 minutes, followed by the addition of 800L FACS buffer to each 
tube and centrifugation to pellet the cells. Supernatant was decanted and cells were 
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resuspended in 300L FACS buffer, followed by overnight storage at 2-6C, wrapped in ultra-
foil, until flow cytometry data acquisition.  
 
 
Table 1.  Antibody panel to detect ILC proliferation in the lungs following BCG vaccination 
for the in-vivo dual labelling experiment.  
 
Specificity Conjugate Manufacturer Clone Lot Titrated 
to 
Detector 
FcRIII -  In-house  2.4G2 -  1:10 -  
Live/Dead FVS700 BD HorizonTM  -  5166794 1:1000 R 730/30 
Lineage PE-Cy5 Biolegend  -  B202412 1:1000 YG 
670/35 
CD45 APC-Cy7 BD 
PharmingenTM 
30-F11 7138715 1:1000 R 780/60 
CD127 PE-Cy7 BD 
PharmingenTM 
SB/199 7039823 1:100 YG 
780/60 
T-bet BV421 BD HorizonTM  4B10 B246190 1:50 V 450/50 
Eomes PE Miltenyi (Berisch 
Gladbach, 
Germany)  
REA116 5170712203 1:10 YG 
586/15 
RORt PE-CF594 BD HorizonTM Q31-
378 
7240624 1:80 YG 
610/20 




- 1:50 R 670/14 





















Table 2. Antibody panel to detect ILC proliferation in the lungs following BCG vaccination 
for the FTY720 experiment.  
 
Specificity Conjugate Manufacturer Clone Lot Titrated 
to 
Detector 
FcRIII N/A In-house  2.4G2 - 1:10 N/A  
Live/Dead FVS700 BD HorizonTM  -  5166794 1:1000 R 730/30 
Lineage PE-Cy5 Biolegend  -  B202412 1:1000 YG 
670/35 
CD45 APC-Cy7 BD 
PharmingenTM 
30-F11 7138715 1:1000 R 780/60 
CD127 PE-Cy7 BD 
PharmingenTM 
SB/199 7039823 1:100 YG 
780/60 
T-bet BV421 BD HorizonTM  4B10 B246190 1:50 V 450/50 
Eomes PE Miltenyi (Berisch 
Gladbach, 
Germany)  
REA116 5170712203 1:10 YG 
586/15 
RORt PE-CF594 BD HorizonTM Q31-
378 
7240624 1:80 YG 
610/20 




Table 3. Biotinylated anti-lineage antibody panel to identify lineage-positive cells.  
 
Specificity  Conjugate  Manufacturer Clone Lot Dilution 
CD3 Biotin  Biolegend 1452C11  B197191  1:400 
CD5 Biotin  Biolegend 53-7.3  B151873 1:800 
CD19 Biotin  Biolegend 6D5  B192314  1:800 
CD11c Biotin  Biolegend N418  B185447 1:400 
TER119 Biotin  Biolegend TER-119  B193723  1:800 
GR1 Biotin  Biolegend RB6-8C5 B180439  1:400 




Table 4. Antibody panel to assess lymphopenia following treatment with FTY720.  
 
Specificity  Conjugate Manufacturer Clone  Lot  Dilution Detector  
Live/Dead  FVS700  BD HorizonTM - 5166794 1:1000  R 730/30  
CD4  Pacific 
Blue  
Biolegend RM4-4 B211707  1:1000  V 450/50  
Lineage  PE-Cy5 Biolegend  -  B202412 1:1000  YG 670/35  





Table 5. Additional antibodies.  
 
Specificity  Conjugate  Manufacturer  Clone  Lot  Dilution  Detector  
F4/80  PE-Cy5  Biolegend  BM8  B198121 1:800  YG 670/30  
 
 
2.9.5 Compensation controls  
The use of a multi-coloured flow cytometry panel requires preceding compensation of flow 
cytometry data using single-stained controls for each fluorescent antibody in the panel.  
 
For the Live/Dead compensation control, unstained cells were suspended in 1mL of 70% 
ethanol and incubated at 4C for 15 minutes to generate a dead population, thereby enabling 
the positive staining of dead cells. For each of the cell surface antibodies, one drop of 
OneComp eBeads (Thermo Fisher Scientific) encompassing both reactive and unreactive 
beads were incubated with 50L FACS buffer and 0.5L of the corresponding antibody for 15 
minutes at 4C, shielded from light. Beads were then washed with 1mL FACS buffer and tubes 
were centrifuged, supernatant was discarded, and the beads were resuspended in 300L 
FACS buffer and stored at 4C until data acquisition.  
 
Lineage staining was conducted in a two-step process. Firstly, biotinylated -lineage 
antibodies bound to the corresponding cell surface lineage marker. Secondly, these -lineage 
antibodies were bound by streptavidin, which is conjugated to the fluorophore PE-Cy5. For 
the streptavidin compensation control, F4/80 antibody conjugated to PE-Cy5 was used in 
place of streptavidin, as streptavidin is unable to bind to OneComp eBeads.  
 
One drop of OneComp eBeads were added to a new FACS tube for each of the intracellular 
markers. Prior to the incubation of beads with antibody, the compensation control tubes 
were taken through the preceding incubation step with 1x Fixation/Permeabilisation buffer. 
Beads were then washed with 1ml of 1x Perm/Wash buffer, and resuspended in 50L of 1x 
Perm/Wash buffer as well as 0.5L of the corresponding antibody. Beads were incubated for 
45 minutes at 4C, with a rocking motion. Following incubation, beads were washed twice 
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with 0.5mL of 1x Perm/Wash buffer and resuspended in 300L FACS buffer. Tubes were 
covered with ultra-foil and stored at 2-6C overnight until flow cytometry data acquisition.  
 
2.10 Flow cytometry data acquisition and analysis  
2.10.1 Data acquisition  
Data was acquired on a BD LSR Fortessa Cell Analyser (BD, San Jose, CA, USA) using FacsDIVA 
software (version 6.2, BD). A minimum of 500,000 events were collected from each sample 
and control tube. FCS files were exported from FacsDIVA and analysed using FlowJo version 
10.3 software (Tree Star, OR, USA). Graphs were created using GraphPad Prism version 8 
software (GraphPad Software Inc., CA, USA).  
 
2.10.2 Cell number calculations   
Cell number was calculated by multiplying the total number of cells as determined by manual 
counting by the frequency of cells in a specific population as determined by flow cytometric 
data.  
 
2.10.3 Statistical analysis 
Statistical analyses were carried out using GraphPad Prism version 8 software (GraphPad 
Software Inc., CA, USA). Most of the data have been presented as medians due to their non-
parametric distribution. Where appropriate, data were presented as the mean ± SEM. 
Multiple comparisons were carried out using the Kruskal-Wallis test followed by Dunn’s 
multiple comparisons test. Pairwise comparisons were made using the Mann-Whitney test to 












3 Results  
Two distinct experimental approaches were used in this project to test the same hypothesis 
that ILCs proliferate in the lungs following BCG vaccination. The first method was a novel in-
vivo dual labelling system using CFSE and BrdU to identify ILCs actively undergoing cell division 
while in the lungs. This method was adapted from a study by McGill and Legge, who 
developed the dual labelling technique to identify CD8+ T cells dividing in the lungs during 
influenza-virus infection.65 CFSE is a fluorescent dye that labels lung-resident lymphocytes 
when administered through the i.n. route by binding to intracellular molecules. BrdU is a 
thymidine analogue that becomes incorporated into the DNA of actively dividing cells, 
thereby enabling in-vivo detection of cell division occurring within the lungs. CFSE was 
administered to mice i.n., followed by i.n and i.p administration of BrdU 2 hours later. Lungs 
were harvested 4 hours after BrdU administration and processed into single-cell suspensions, 
and cells were stained with antibodies against surface and intranuclear markers to identify 
proliferating ILCs in the lungs.  The second method involved the use of an immunomodulatory 
drug called FTY720 to block lymphocyte egress from secondary lymphoid tissue, and will be 
discussed later.  
 
For the both studies, the protocol for antibody labelling of intranuclear transcription factors 
needed to be optimised, in order to enable detection of NK cells (Eomes+), ILC1s (T-bet+), and 
ILC3s (RORt+) in the lungs.  
 
3.1 Optimisation of T-bet transcription factor staining  
The antibody labelling of the transcription factors Eomes and RORt was sufficient, as distinct 
populations of cells expressing these transcription factors were detectable by flow cytometry. 
However, there was a recurrent issue with the T-bet transcription factor staining, exemplified 
by the lack of a distinct T-bet-positive population. Therefore, the aim of these experiments 
was to optimise the protocol for the antibody labelling of the T-bet transcription factor, to 
enable identification of a T-bet positive population.  
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3.1.1 Stimulation with PMA and ionomycin   
During the initial protocol optimisation experiments, murine cells required overnight 
stimulation with PMA and ionomycin in order to stimulate lymphocyte transcription factor 
expression to allow for phenotypic analysis, as these cells were obtained from naïve mice and 
were therefore expected to have low polarised lymphocyte transcription factor expression.  
 
Stimulation with PMA and ionomycin bypasses the T cell receptor complex, leading to the 
activation of various intracellular signalling cascades that result in T cell activation.66 The 
initial concentrations at which PMA and ionomycin were added to cells were 5ng/mL and 
0.5g/mL respectively, as these are within the concentration ranges typically used in the 
literature for this type of protocol.67,68  It was hypothesised that inadequate cell activation 
was the reason for previous failure of T-bet staining, and that increasing the concentration at 
which PMA and ionomycin were added to the cells would result in successful T-bet staining. 
However, doubling the concentration of PMA from 5ng/ml to 10ng/mL and ionomycin from 
0.5g/mL to 1g/mL had no apparent effect on T-bet staining efficacy, as there was no 





Figure 1. No improvement of T-bet staining efficacy upon doubling the concentration of PMA and 
ionomycin during stimulation.  
 
Splenocytes were prepared from a naïve C57BL/6 mouse spleen and stimulated overnight with either 
5ng/mL PMA and 0.5g/mL ionomycin, or 10ng/mL PMA and 1g/mL ionomycin, and then stained with 
viability stain and anti-T-bet antibody for flow cytometry. Cells were gated on live lymphocytes, and 
then T-bet gates were set using FMO controls for each stimulation condition.  
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3.1.2 Transcription Factor Buffer Kit comparison  
Since increasing the concentration of PMA and ionomycin did not affect the T-bet staining, I 
hypothesised that the BD Transcription Factor Buffer Staining Kit used in the protocol was 
either defective, or insufficient in enabling the detection of T-bet. Therefore, a comparison of 
two different intranuclear staining transcription buffer kits was carried out, to determine 
whether the kit reagents had any impact on the T-bet staining efficacy. Stimulated murine 
splenocytes were divided into two different sample tubes: sample 1 was treated using the BD 
Transcription Factor Buffer Staining Kit, and sample 2 was treated using the BrdU Flow Kit. No 
major difference in the T-bet staining efficacy between the two staining kits was observed 
(Fig. 2). There was a slight increase in the frequency of T-bet-positive cells when using the BD 





3.1.3 Doubling anti-T-bet antibody concentration and increasing rocking speed during 
incubation period  
Previous work determined the optimal dilution of anti-T-bet antibody to achieve sufficient 
fluorescence intensity with minimal background staining to be 1:100; however, the labelling 
of T-bet at this dilution was unsatisfactory. It was hypothesised that doubling the 
concentration of anti-T-bet antibody from a 1:100 dilution to a 1:50 dilution would result in 
Figure 2. T-bet staining failed regardless of the transcription factor buffer kit used. 
 
Splenocytes were prepared from a naïve C57BL/6 mouse spleen and stimulated overnight with 5ng/mL PMA 
and 0.5g/mL ionomycin, and then stained with viability dye and anti-T-bet antibody for flow cytometry. 
Cells were gated on live lymphocytes, and then T-bet gates were created using FMO controls. Flow plots 
show T-bet staining following use of the BD Transcription Factor Buffer Staining Kit compared to T-bet 
staining following use of the BrdU Flow Kit.  
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successful staining due to a larger quantity of antibody contacting the cells. As shown in Fig. 
3A, this modification lead to a modest improvement in the T-bet staining efficacy compared 
to previous attempts shown in Figs. 1 and 2. In addition, increasing the rocking speed to a 
higher setting during the incubation with intranuclear antibody master mix further enhanced 
the T-bet staining efficacy (Fig. 3B), enabling the identification of a definitive T-bet-positive 
population. Therefore, in future experiments the combination of doubling the anti-T-bet 
antibody concentration and increasing the rocking speed during the incubation period was 






3.2 Verification of the ability of CFSE to label lung cells 
CFSE is a vital component of the dual-labelling system used to identify proliferating ILCs in the 
lungs, as it labels all lymphocytes present in the lung when administered to mice through the 
i.n. route. Therefore, the ability of CFSE to successfully label cells had to be confirmed.  Before 
progressing to testing the CFSE staining efficacy in-vivo, it was first added to cells in-vitro to 
confirm the ability of CFSE to label lymphocytes. The CFSE staining of lymphocytes in-vitro 
was successful, with 100% of cells labelled CFSE-positive (Fig. 4A).  
 
Figure 3. Modest improvement in T-bet staining efficacy upon doubling of the anti-T-bet antibody 
concentration; further improvement with increased rocking speed.  
 
Splenocytes were prepared from a naïve C57BL/6 mouse spleen and stimulated overnight with 5ng/mL PMA 
and 500ng/mL ionomycin, and then stained with viability dye and anti-T-bet antibody at a 1:50 dilution (A 
and B). In B) the rocking speed during the incubation of cells with intracellular antibody master mix was 
increased. Cells were gated on live lymphocytes, and then T-bet gates were created using FMO controls.   
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Next, CFSE was administered i.n. to a mouse 6 hours prior to tissue harvest, to examine the 
ability of CFSE to label lung-resident lymphocytes. This experiment showed that the CFSE 
efficiently labelled lung lymphocytes, as 99.8% of the lymphocyte population obtained from 
lung tissue were CFSE-positive following in-vivo administration of CFSE through the i.n. route 
(Fig. 4B). The relative absence of CFSE in splenocytes taken from the same mouse (Fig. 4C) 















Figure 4. CFSE efficiently and specifically labelled lymphocytes of the lung.   
 
Biaxial flow cytometry plots showing CFSE-positive populations: A) Lymphocytes from a C57BL/6 
mouse lung were pulsed with CFSE in-vitro, B and C) CFSE was administered i.n. to a C57BL/6 mouse 
6 hours prior to lung harvest: The resulting CFSE staining of lung lymphocytes is shown in B; CFSE 
staining of splenocytes from the same mouse is shown in C.  
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3.3 Verification of the ability of BrdU to label dividing cells  
 
BrdU is the second vital component of the dual-labelling system used to identify proliferating 
ILCs in the lungs, as it incorporates into the DNA of all diving cells in the mouse. Therefore, 
the ability of BrdU to incorporate into dividing cells in-vivo had to be confirmed. The BrdU 
labelling of cells undergoing division was successful, as evidenced by a distinct BrdU-positive 















Figure 5. BrdU labelling of live lymphocytes was detected by flow cytometry.  
BrdU was administered i.n. and i.p to a C57BL/6 mouse 4 hours prior to lung 
harvest. The lungs were processed into a single-cell suspension, and lymphocytes 
were stained with viability dye and anti-BrdU antibody. The resulting BrdU 
staining, gated on live lymphocytes, is shown above.  
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3.4 In-vivo dual labelling system to identify the anatomical site of ILC 
proliferation  
3.4.1 Experiment design  
To examine the kinetics and site of ILC proliferation following BCG vaccination, 3 mice were 
vaccinated with BCG at each pre-defined time point prior to tissue harvest. The proliferation 
of ILCs in response to BCG was then able to be measured at 1.5, 2.5, 3, 3.5, and 4 weeks post-
vaccination. One group of mice remained unvaccinated as a negative control. Mice were 
administered with i.n. CFSE and i.n. + i.p. BrdU as described in section 2.4, followed by 
harvesting of the lungs and spleen and processing of these tissues into single-cell suspensions. 
Cells were then labelled with antibodies against lineage makers, CD45, and CD127, followed 
by labelling of the intranuclear markers T-bet, RORt, Eomes, and BrdU. Events were acquired 




Figure 6. Schematic of the experiment design and timeline for the dual-labelling experiment to examine the 
kinetics and site of ILC proliferation.  
  
A group of three age- and sex-matched mice was given an i.n. vaccination of 105 CFU BCG Pasteur at each of 
the following time points prior to lung harvest: 1.5, 2.5, 3.0, 3.5, and 4.0 weeks. Four mice remained as 
unvaccinated controls. When the experimental endpoint was reached, all mice except one were given i.n. CFSE, 
followed by i.n.  and i.p. BrdU to all mice 2 hours later. Mice were culled 4 hours following BrdU administration, 
tissues were harvested and processed into single-celled suspensions, cells were labelled with antibodies 




3.4.2 Markers used to identify lung-resident proliferating ILCs  
Doublet and debris exclusion was performed first by plotting area against height for forward 
scatter (FSC) and then for side scatter (SSC), to ensure only single cells were included in the 
analysis. Doublets have double the area compared to their height, and were therefore 
identified by their disproportionate area and height parameters. Cells were then gated on 
viable cells which had excluded the viability dye, followed by gating on the lymphocyte 
population, as distinguished by FSC (size) and SSC (granularity) parameters. Cells expressing 
the common leukocyte antigen, CD45, were then gated on, as this is expressed on all 
leukocytes including ILCs.69 From the CD45+ gate, the lineage negative population was then 
gated on. The lineage panel enables the exclusion of mature myeloid and lymphoid cells which 
express lineage markers. These include T lymphocytes (CD3+ and CD5+), B lymphocytes 
(CD19+), dendritic cells (CD11c+), erythrocytes (TER119+), myeloid cells (GR-1+), and 
macrophages (F4/80+). ILCs typically do not express these lineage markers.  
 
ILC subsets were then distinguished by their preferential expression of the master 
transcription factors T-bet, RORt, or Eomes; T-bet is expressed by ILC1s,70 RORt is expressed 
by ILC3s, and Eomes is expressed by NK cells. ILC1s and ILC3s were further characterised by 
their expression of CD127, which forms the interleukin-7 receptor- subunit of the 
interleukin-7 receptor, and is required for ILC1 and ILC3 survival.71 CD127 is not required for 
NK cell survival, therefore the absence of CD127 was used to confirm the identity of NK cells.  
 
Once the ILC subsets were identified, the percentages of CFSE+ and BrdU+ cells were 


















Figure 7. Representative biaxial flow cytometry plots depicting the gating strategy used to identify 
proliferating ILCs in the lungs following BCG vaccination. 
 
Lymphocytes were harvested and events were acquired using a BD LSR Fortessa. Firstly, two singlet gates 
were made (using FSC (A) and SSC (B)), followed by gating on lymphocytes (C). Live lymphocytes were then 
gated on (D), followed by CD45+ cells (E). The lineage-negative population were then selected (F), for gating 
on markers to identify the different ILC subsets. ILC1s were identified as T-bet+ (G) and CD127+ (H); NK cells 
were identified as Eomes+ (J), and CD127- (K); and ILC3s were identified as CD127+ (M) and RORt+ (N). 




3.4.3 BCG vaccination enhanced the proportion of proliferating ILCs within each subset  
A main objective of this research project was to establish the optimal time to measure ILC 
proliferation to be induced after BCG vaccination (Fig. 8). An increase in ILC proliferation was 
detected in all subsets at 1.5 weeks post-vaccination, and remained elevated across all time 
points measured (1.5 – 4 weeks). The greatest increase in the proportion of proliferating ILCs 
occurred at 3.5 weeks post-vaccination for NK cells (Fig. 8A) and ILC1s (Fig. 8B), and at 3 weeks 
for ILC3s (Fig. 8C). However, these results were not statistically significant. In order to 
corroborate these findings and achieve statistical significance, this experiment will be 
repeated at the 3.5 week time point with a larger number of animals per group, established 






















































































































































Figure 8. BCG enhanced the proportion of proliferating lung ILCs between 1.5 - 4 weeks post-vaccination.  
Mice vaccinated with 105 CFU BCG Pasteur at either 1.5, 2.5, 3, 3.5, or 4 weeks prior to lung harvest were 
administered i.n. CFSE and i.n. + i.p. BrdU as described in section 2.4.  Lungs were harvested and processed into 
single-cell suspensions, and cells were stained with antibodies to identify proliferating ILCs in the lungs. Bar graphs 
show the median percentage of A) NK cells, B) ILC1s, and C) ILC3s  which were proliferating within the lungs at 
various time points following BCG vaccination. Medians are presented from n = 2-3 mice per time point. Data were 
analysed using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
Time post-vaccination (weeks)
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3.4.4 ILCs increased in number following BCG exposure  
In addition to the increase in the proportion of proliferating ILCs, there was also an increase 
in the total number of ILCs within each subset in the lungs between 1.5 – 4 weeks post-
vaccination with BCG (Fig. 9). NK cells, ILC1s, and ILC3s were all present in the greatest 
numbers at 4 weeks post-vaccination, and this was a statistically significant increase 
compared to unvaccinated controls. Additionally, within the ILC1 subset, the number of cells 
at 4 weeks was significantly greater than the number of cells at both 1.5 and 3 weeks post-




















3.4.5 ILCs primarily divided within the lungs following BCG vaccination  
Another main objective of this research project was to determine the anatomical site of ILC 
proliferation following i.n. vaccination with BCG. Figure 10 illustrates the percentage of 
dividing ILCs (BrdU positive) which were also CFSE positive, and therefore dividing within the 
lungs. Within each ILC subset and across all time points following BCG vaccination a majority 
of proliferating ILCs were dividing within the lungs. For NK cells, the percentage of BrdU+ cells 
which were also CFSE+ ranged from 97.2% to 100% with a mean of 99.65.  Similarly, for ILC1s 
the percentages ranged from 94.7% to 100% with a mean of 99.29% and for ILC3s the range 
was from 93.4% to 100% with a mean of 99.63%. The median percentage for each ILC subset 
and across all time points was 100%.  These data support the hypothesis that ILCs divide 






























































































































































Figure 10. ILCs primarily divide within the lungs after BCG exposure. 
Mice vaccinated with 105 CFU BCG Pasteur either 1.5, 2.5, 3, 3.5, or 4 weeks prior to lung harvest were 
administered i.n. CFSE and i.n. + i.p. BrdU as described in section 2.4.  Percentages of BrdU+ cells which 
were also CFSE+ at each time point within each ILC subset were quantified using flow cytometry: A) NK 




3.5 The use of FTY720 to determine the site of ILC proliferation 
following BCG vaccination  
To corroborate the finding that ILCs divide within the lung following BCG vaccination, an 
alternative approach using FTY720, an immunomodulatory drug which inhibits lymphocyte 
egress from secondary lymphoid tissue,72 was employed. Sphingosine‐1‐phosphate-1 (S1P1) 
receptors expressed by lymphocytes facilitate the cellular migration along S1P gradients and 
the subsequent exit from the lymph nodes (LN) and spleen. FTY720 acts as a S1P1 receptor 
agonist to induce internalisation of these receptors, thereby preventing lymphocyte 
emigration from these tissues. This mechanism therefore enables testing of the hypothesis 
that ILCs proliferate locally within the lungs as it prevents new recruitment of ILCs from the 
spleen and LN to the lungs. Proliferation of ILCs in the lungs in FTY720-treated mice can be 
interpreted as independent of new cell recruitment, and rather a function of lung-resident 




























Figure 11. Schematic of experiment design and timeline for the use of FTY720 to determine the site of ILC 
proliferation following BCG vaccination.  
 
FTY720 was administered to mice in group 1 dissolved in drinking water at a concentration of 2g/ml in a volume 
of 5ml per mouse per day. This commenced at day -2, and was available to the mice ad-libitum until day 28, 
where the experimental endpoint was reached and the mice were culled.  On day 0, mice in groups 1 and 2 
received an i.n vaccination of 105 CFU BCG. Tail bleeding of mice in groups 1 and 2 was conducted on day 7 and 
day 14 to confirm lymphopenia in FTY720-treated mice. Mice in group 3 remained unmanipulated during the 
course of the experiment to serve as a control group. On day 28, all mice were culled, lungs were harvested, and 
single-cell suspensions were generated. Cells were stained with antibodies for the surface and intranuclear 
markers of interest, followed by acquisition of data on the BD LSR Fortessa.  
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3.5.1 Treatment with FTY720 successfully induced lymphopenia in mice   
Mice were tail-bled during the course of the experiment to confirm the efficacy of FTY720 in 
preventing lymphocyte egress from secondary lymphoid tissue. Due to the relative paucity of 
ILCs in peripheral blood, the frequency change in total lymphocytes, CD4+ T cells, and CD8+ T 
cells following treatment with FTY720 was used as a surrogate measure of ILC depletion for 
most time-points assessed. Compared to control mice, FTY720-treated mice experienced a 
statistically significant reduction in lymphocytes, CD4+ T cells and CD8+ T cells after 14 days 



















3.5.2 Gating strategy to identify proliferating ILCs following BCG vaccination for the 










Figure 13. Representative biaxial flow cytometry plots depicting the gating strategy used to identify 
proliferating ILCs in the lungs at various time points following BCG vaccination.   
 
Lymphocytes were harvested and events were acquired using a BD LSR Fortessa. Firstly, two singlet gates were 
made (using FSC (A) and SSC (B)), followed by gating on lymphocytes (C). Live lymphocytes were then gated 
on (D), followed by CD45+ cells (E). The lineage-negative population were then selected (F), for gating on 
markers to identify the different ILC subsets. ILC1s were identified as T-bet+ (G) and CD127+ (H); NK cells were 
identified as Eomes+ (J), and CD127- (K); and ILC3s were identified as RORt+ (M) and CD127+ (N). Ki-67+ ILCs 
within each subset were then quantified (I, L, O).  
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3.5.3 ILC proliferation in the lungs was not impaired by treatment with FTY720  
As expected, BCG vaccination led to significant proliferation of ILC populations in the lungs at 
4 weeks post-vaccination (Fig. 1.4). For each ILC subset, the percentage of proliferating ILCs 
was similar between BCG-vaccinated mice which received FTY720 and those that did not 
receive FTY720, and was significantly greater than the control group. These data suggest that 
the inhibition of lymphocyte immigration to the lungs from secondary lymphoid tissue did not 
impair ILC proliferation within the lungs, indicating the presence of lung-resident ILC 
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Figure 14. An increase in Ki-67+ ILCs was elicited by BCG exposure.  
FTY720 was administered continuously to one group of mice from day -2 until day 28. On day 0, two groups of mice 
received an i.n vaccination of 105 CFU BCG. Mice in group 3 remained unmanipulated during the course of the 
experiment. On day 28, all mice were culled, lungs were harvested, and single-cell suspensions were generated. 
Cells were stained to identify proliferating NK cells, ILC1s, and ILC3s in the lungs. Bar graphs illustrate the 
percentage of: A) NK cells, B) ILC1s, and C) ILC3s expressing Ki-67 at 4 weeks post-vaccination with BCG. 
Statistical analyses were carried out using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test. 
Medians are presented for n = 8 mice per group. * P  £ 0.05;  ** P £ 0.01;  *** P £ 0.0005.
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3.5.4 FTY720 did not reduce the total number of ILCs and the number of proliferating ILCs 
after BCG exposure  
 
Total ILC numbers in each subset at 4 weeks post BCG vaccination were calculated and 
compared between groups to determine whether FTY720 treatment altered the total number 
of ILCs in the lung following BCG exposure. Although there appeared to be a small reduction 
in the total number of NK cells and ILC1s in the lungs of the FTY720-treated group of mice, 
this was not statistically significant. Compared to unvaccinated control mice, a statistically 
significant increase in the number of NK cells, ILC1s, and ILC3s was observed in both groups 
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Figure 15. FTY720 did not reduce the total number of ILCs and the number of proliferating ILCs after 
BCG exposure 
FTY720 was administered continuously to one group of mice from day -2 until day 28. On day 0, two groups of 
mice received an i.n vaccination of 105 CFU BCG. Mice in group 3 remained unmanipulated during the course 
of the experiment. On day 28, all mice were culled, lungs were harvested, and single-cell suspensions were 
generated. Cells were stained to identify proliferating NK cells, ILC1s, and ILC3s in the lungs. Bar graphs show 
the median number of A) NK cells, B) ILC1s, and C) ILC3s in the lungs at 4 weeks post-vaccination with BCG, 
comparing between FTY720-treated BCG vaccinated mice, mice who received BCG vaccination alone, and 





4 Discussion  
 
There were two main objectives of this research project. The first was to extend previous 
findings by the Kirman Laboratory, which demonstrated an accumulation of ILC1s and ILC3s 
in the murine lung at 4 weeks post-vaccination with BCG, by establishing whether or not this 
increase was a result of local ILC expansion within the lungs.  The second objective was to 
explore the kinetics of ILC proliferation to determine when the peak ILC expansion in response 
to BCG occurs. Previous research established that ILC proliferation was increased at 4 weeks 
post-vaccination with BCG; the current project aimed to determine whether proliferation was 
evident even earlier than this.  
 
Understanding the anatomical site of ILC proliferation following exposure to BCG is an 
important concept when considering vaccine design. For example, the local expansion of 
these cells within the lungs mean they would be best targeted through the intranasal or 
aerosol vaccination routes. Determining the site of ILC proliferation is also assists in 
characterising the role of these cells in anti-mycobacterial immunity, an area of research in 
which there a current lack of knowledge.   
 
The aims of this research project were addressed through the use of two distinct methods:  
1. A novel in-vivo dual labelling system adapted from McGill and Legge’s published work.  
2. The use of immunomodulatory drug FTY720 to block lymphocyte egress from 
secondary lymphoid tissue.  
 
The data generated from this project showed that ILCs primarily divided within the lungs 
following BCG vaccination. Of the time points measured, the greatest accumulation of ILCs 
occurred at 4 weeks post-vaccination. An increase in the proportion of proliferating NK cells, 
ILC1s and ILC3s within the lung was detectable at all time points measured between 1.5 and 
4 weeks after vaccination, but was greatest at 3.5 weeks post-vaccination for NK cells and 




4.1 Main findings of this research project  
4.1.1 ILC proliferation was enhanced between 1.5 – 4 weeks post-vaccination  
Analyses from the in-vivo dual labelling experiment revealed the total numbers of NK cells, 
ILC1s and ILC3s were elevated at 1.5, 2.5, 3, 3.5, and 4 weeks post BCG vaccination compared 
to unvaccinated mice. However, the only statistically significant increase compared to 
unvaccinated mice was observed at 4 weeks post-vaccination.  
 
NK cells, ILC1s, and ILC3s were all present in the greatest number at 4 weeks post vaccination, 
at numbers significantly greater than those in unvaccinated control mice. This result is 
concordant with previous findings from the Kirman Laboratory,64 which revealed a substantial 
elevation in the numbers of NK cells, ILC1s, and ILC3s at 4 weeks post-vaccination with i.n. 
BCG Pasteur, using a surface marker panel to define ILC subsets rather than using 
transcription factors.  This previous study also found that ILC numbers had regressed and 
were comparable to those in unvaccinated mice at 12 weeks post-vaccination. It would be 
interesting to examine ILC expansion in the lungs between 4 and 12 weeks post-vaccination 
to determine which time point marks the beginning of the contraction phase of the ILC 
proliferation response.  
 
An early expansion of NK cells, ILC1s, and ILC3s at 1.5 weeks post-vaccination with BCG was 
detected. This result is in accordance with findings from a study analysing the kinetics and 
function of NK cells in response to an aerosol challenge of Mtb,73 which reported a significant 
increase in NK cells as early as 1 week post-infection with Mtb.  
 
4.1.2 BCG-induced alterations in the relative abundance of ILCs in the lung  
Data from the in-vivo dual labelling experiment show a greater proportional increase in the 
total number of ILC1s compared to ILC3s between 1.5 and 4 weeks post-vaccination with BCG. 
ILC3s are known to be the most abundant ILC subset in the human lung, accounting for 60% 
of total ILCs in this tissue.26 ILC2s are the most prevalent ILC subset in the mouse lung, 
however there is little known about the relative ratios of ILC1s and ILC3s in mice.  
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ILCs exhibit a high degree of plasticity and can alter their phenotype and function to adapt to 
the microenvironment.74 It has been shown that exposure of ILC3s to IL-12 can induce a loss 
of RORt expression with a corresponding acquisition of ILC1-like properties in these cells, 
including the expression of T-bet and the production of IFN-.75 IL-12 is important for T cell 
activation, polarisation, and survival during Mtb infection, meaning this cytokine is likely to 
be present in the microenvironment.76 IL-12 secreted by activated antigen-presenting cells 
assists in the development of a Th1-like immune response, leading to copious amounts of IFN-
 secretion, which is crucial for a successful pro-inflammatory immune response during Mtb 
infection.  Therefore, the transdifferentiation of ILC3s into ILC1s may enhance the magnitude 
of the anti-mycobacterial immune response. A protective role for the ILC3 effector cytokine 
IL-22 in the immune response to TB has been identified77 but is less well-established, and 
perhaps less important compared to a Th1-like immune response.   
 
 
4.1.3 ILCs divided within the lungs following BCG vaccination 
ILC migration to the lungs from the LN and spleen was inhibited by the administration of 
FTY720, enabling the assessment of ILC proliferation within the lungs independent of new cell 
recruitment. This experiment showed that BCG vaccination enhanced both the proportion 
and number of proliferating ILCs in the lungs irrespective of whether or not the mice received 
FTY720, indicating the presence of lung-resident ILC populations which divide in response to 
BCG. This result was concordant with the results from the in-vivo dual labelling experiment, 
which also showed that most dividing ILCs divided within the lung. Together, the data 
generated by these two separate experiments provide robust evidence favouring the 
hypothesis that ILCs proliferate locally within the lungs after vaccination with BCG.  
 
These findings are in accordance with a recent study by Yamamoto et al, which reported lung-
resident expansion of NK cells which were important in controlling pulmonary tumour growth 
in mice.78 Similarly to my project, this study used FTY720 to block new lymphocyte 
recruitment to the lung. No significant difference in pulmonary tumour growth was found 
between mice which received FTY720 and mice which did not, indicating the importance of 




These findings have far-reaching implications for the design of vaccines to prevent TB. The 
future of TB vaccine design may witness the relative obsoletion of T cell-oriented vaccines, as 
thus far there has been little evidence of a protective memory immune response induced by 
vaccines targeting T cells. The discovery of ILCs possessing memory-like qualities, in 
conjunction with the enrichment of ILCs at mucosal surfaces and their ability to proliferate 
within the lungs, means a mucosal vaccine targeted to these cells may offer some potential.  
  
4.2 Models for studying mycobacterial infection    
4.2.1 Choice of the murine model for this study   
Due to the complexity of mammalian immunological responses to the inflammatory 
bacterium, Mtb, examining aspects of the immune response following vaccination with BCG 
requires a whole-animal biological system. Mice were chosen for this study as they are a cost-
effective, convenient, manipulatable tool representing the complexity of vertebrate 
immunity in the context of mycobacterial infection, and can therefore be used to study the 
effect of BCG on ILC proliferation. Furthermore, immunological tools and reagents for 
studying ILC proliferation in the murine model, such as monoclonal antibodies, are readily 
available.  
 
4.2.2 Choice of BCG Pasteur strain 1173P2   
To maintain the stock, BCG had to be continuously grown in culture at the Pasteur Institute 
in France following its initial development, as freeze-drying had not yet been introduced.79 As 
a result, 1,173 serial passages had been conducted since the original vaccine was produced 
until 1961, when freeze-drying was made possible. This particular strain was titled BCG 
Pasteur 1173P2.  
 
BCG Pasteur strain 1173P2 is known to be immunogenic and has proven to induce an immune 
response in previous studies by the Kirman Laboratory.64 Further, BCG Pasteur has the highest 
total global production level compared to any other strain, and is the most commonly used 
strain in current vaccination schemes around the world. Therefore, the results generated 
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using this strain are the most applicable beyond the realms of this study; if a rare strain of 
BCG was in these experiments the results would not be generalisable.  
 
4.3 Optimisation of the intranuclear T-bet staining protocol  
During the protocol validation and optimisation phase of this project, there was a recurrent 
issue within the T-bet intranuclear transcription factor staining. It was expected that 
overnight stimulation with PMA and ionomycin to stimulate lymphocyte transcription factor 
expression would give rise to a distinct T-bet positive population.  However, insufficient T-bet 
staining was observed following overnight stimulation. This poor staining of T-bet was not 
rescued by doubling the concentration of PMA and ionomycin for the overnight stimulation, 
which suggested that the issue resided within the intranuclear staining protocol, rather than 
the expression of T-bet itself.  
 
The next step was to investigate the possibility that the BD Transcription Factor Buffer 
Staining Kit was either defective, or insufficient in enabling the detection of T-bet, by 
repeating the protocol using another type of transcription factor staining kit: the BrdU Flow 
kit. Both of these kits serve the same purpose of fixing cellular proteins and permeabilising 
cells to facilitate immunofluorescent staining of nuclear transcription factors. A comparison 
of T-bet staining following the use of the BD Transcription Factor Buffer Staining and the use 
of the BrdU Flow Kit revealed poor staining of T-bet regardless of which kit was used in the 
protocol, discounting the hypothesis that the BD Transcription Factor Buffer kit was 
responsible for the defective staining of T-bet.  
 
It was then hypothesised that doubling the anti-T-bet antibody would improve the staining 
efficacy. Indeed, a modest improvement in T-bet staining was observed following this 
alteration to the protocol. It was found that T-bet staining was further augmented by 
increasing the rocking speed during the incubation of cells with intranuclear antibody master 
mix, perhaps due to more thorough distribution of antibody amongst cells through an 
enhanced collision rate. It was concluded that doubling the concentration of anti-T-bet 
antibody in conjunction with an increased rocking speed enabled the successful staining of 
the T-bet transcription factor.  
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4.4 Flow Cytometry panel used in this study  
The flow cytometry panel used in this study identified ILC subsets based on the presence or 
absence of particular surface markers and intranuclear transcription factors, and there are 
some potential concerns associated with this. ILCs were categorised as lineage-negative 
during the gating strategy, as they typically lack expression of the lineage markers CD3, CD5, 
CD19, CD11c, TER119, GR-1, and F4/80. However, some NK cells have been shown to express 
CD11c.80 CD11c was included in the lineage panel to exclude DCs, and therefore also excluded 
CD11c-expressing NK cells. This is a notable limitation as CD11c upregulation on NK cells been 
associated with an activated immune phenotype with enhanced production of IFN- during 
inflammation,81 and these CD11c+ NK cells are therefore likely to be important in the immune 
response to TB. It would be useful in further studies to include CD11c+ NK cells in order to 
examine whether this alters the number of expanding ILCs in the lungs, and therefore provide 
insight into the significance of this CD11c+ population in anti-mycobacterial immune 
responses.   
 
The lineage panel included anti-CD3 antibody to exclude T cells during the gating strategy, as 
CD3 forms part of the TCR complex expressed on the surface of T cells. It has been shown that 
internalisation of CD3 can occur upon T cell activation,82 which opens the possibility of 
including some T cells in the lineage-negative gate. However, in this study the panel also 
included another lineage marker, CD5, which is expressed on the T cell surface; therefore, the 
inclusion of two different T cell markers in the lineage panel would have likely led to the 
sufficient exclusion of T cells in the lineage-negative gate.  
 
The heterogeneous and plastic nature of ILCs gives rise to some limitations when 
distinguishing ILC subsets on the basis of their transcription factor expression. For example, 
in this study NK cells were identified as Eomes+, and ILC1s were identified as T-bet+; however, 
co-expression of both Eomes and T-bet in some NK cell populations has been reported,83 as 





4.5 Project methodology: In-vivo dual labelling method    
4.5.1 Adaptation of McGill and Legge’s in-vivo dual labelling technique to identify the site 
of ILC proliferation.  
The in vivo CFSE and BrdU labelling method used to identify cell proliferation in the lung was 
adapted from a study by McGill and Legge, who developed the dual labelling technique to 
identify CD8+ T cells dividing in the lungs during influenza-virus infection. When given to mice 
i.n., CFSE labels all lung-resident lymphocytes, and then the subsequent i.n. and i.p. 
administration of BrdU labels all proliferating cells within the mouse. Therefore, not only can 
cell proliferation be assessed, but the site at which division is occurring can also be elucidated. 
Identifying the site of proliferation of an immune cell subset in response to a particular 
pathogen is an important concept when targeting this immune population in vaccine 
development. This is particularly important in TB vaccine development, where vaccine-
induced immune correlates of protection are poorly understood.  
 
4.5.2 The use of BrdU as a marker of proliferation  
There are several potential concerns associated with the use of BrdU as a marker of 
proliferation. BrdU incorporates into nuclear DNA during synthesis, and by doing so labels 
cells undergoing DNA repair as well as labelling cells undergoing division. Thus, the level of 
BrdU-positive cells in the lung may not correlate exactly to the degree of cell proliferation 
occurring within the lungs.  
 
Another limitation of using BrdU as a marker of proliferation is that it only incorporates into 
nuclear DNA during the S phase of the cell cycle (DNA synthesis). In comparison, Ki-67 is 
expressed by cells during the entire mitotic cell cycle (G1, S, G2, and M phases) and has a 
short half-life, making it a reliable and accurate marker of cell division. A study by Kee et al 
demonstrated that using Ki-67 as a proliferation marker detected 50% more cells than using 
BrdU.84 The use of BrdU in the in-vivo dual labelling experiment may have therefore 
underestimated the degree of cell division occurring in the mice, and may account for the 
lower percentages of dividing ILCs observed in this experiment compared to the greater 
percentages observed in the FTY720 experiment, which used Ki-67 to measure proliferation. 
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The use of Ki-67 was not suitable for the in-vivo dual labelling experiment; the endogenous 
expression of Ki-67 by cells undergoing proliferation does not allow for the preceding staining 
of the lungs before identifying proliferating cells. For example, proliferating cells expressing 
Ki-67 could migrate into the lungs prior to, or during, the administration of CFSE, i.e. they may 
be completing their division programme upon entry into the lungs. This would translate into 
false-positive results suggesting that these cells had divided within the lungs, when they had 
actually began dividing prior to migration into the lungs. Therefore, cell proliferation needs 
to be assessed using a regent that can be administered following the initial staining of lung 
cells with CFSE.  
 
A further important potential limitation of BrdU is that as an exogenous addition to nuclear 
DNA, newly incorporated BrdU has the potential to alter cell cycle progression: cytostatic and 
cytostatic effects or BrdU incorporation have been reported.85 
 
Another possible alternative marker of cell proliferation is the BrdU analogue 3H-Thymidine 
(3H-dT), a radioactive nucleoside which, similarly to BrdU, becomes incorporated into 
synthesising DNA.86  3H-dT has been shown to be less cytotoxic than BrdU and has a high 
degree of similarity to the normal endogenous nucleoside, whereas BrdU introduces a 
completely foreign atom when incorporated into DNA, which may have consequences on cell 
cycle progression. However, there are economic and time constraints associated with the use 
of 3H-dT to measure cell division, as well as concerns regarding the use of radioactive material, 
rendering it unsuitable for this project.  
 
More recently, a further potential alternative marker of cell division is the BrdU analogue 5-
ethynyl-2’-deoxyuridine (EdU), which provides a rapid, simple, and sensitive measure of DNA 
synthesis.87 Simialrly to BrdU, EdU is a thymidine analogue and incorporates into de novo DNA 
of actively dividing cells. EdU is detectable by a method called click chemistry, which is the 
covalent linkage of its ethynyl group with a fluorescent azide, a small molecule which 
passively diffuses through tissue and DNA. This would circumvent the requirement for DNA 
denaturation to allow anti-BrdU antibody binding of exposed BrdU in genomic DNA.  
However, EdU is a relatively new method of detecting cell proliferation, and vigorous testing 
of this molecule in a variety of biological research settings has not yet been conducted, nor 
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has it been used in the context of McGill and Legge’s in vivo dual labelling system. BrdU was 
therefore chosen for this project, as it was utilised successfully in McGill and Legge’s research.  
 
4.5.3 The use of CFSE to label cells of the lung  
Following i.n. administration of CFSE, the mean percentage of lung cells which were stained 
CFSE-positive, gated on live lymphocytes, was 97.5%, which suggested a high efficacy of CFSE 
in labelling lung lymphocytes. CFSE was administered 6 hours prior to tissue harvest, allowing 
sufficient time for CFSE to enter cells and covalently couple to intracellular proteins. (3). 
Lymphocyte migration into the lungs from other anatomical sites such as draining lymph 
nodes during the 6 hours following CFSE administration may account for the remaining CFSE-
negative lung cells.  
 
To confirm the specificity of CFSE labelling, spleens from mice which had received i.n. CFSE 
were analysed for the presence of CFSE. The mean percentage of splenocytes which were 
stained CFSE positive was 0.8%, thus confirming that CFSE was specifically labelling cells 
within the lung. In future experiments, it would be beneficial to also assess the presence of 
CFSE in lymph nodes, to further confirm that the dye was only labelling cells of the lung.   
 
The success of CFSE in cell labelling assays can be attributed to two main chemical properties 
of the dye. The first is the presence of two acetate groups which make the dye highly 
membrane-permeant, allowing it to rapidly traverse the plasma membrane of cells.88 The dye 
then concentrates within cells due to cleavage of the acetates by esterases, giving rise to 
anionic CFSE, a less membrane-permeable form of the dye. The second important property 
of CFSE is its amino-reactive succinimidyl side chain, which enables covalent coupling of the 
dye to intracellular proteins, resulting in a high level of stable fluorescence. The long-lived 
fluorescence of high intensity and low variability make CFSE a useful in-vivo cell labelling 
method for experiments involving flow cytometric analyses.  
 
One disadvantage associated with the use of CFSE labelling is the cytotoxic effects and other 
alterations to cell function and behaviour that this dye may have on cells. A study by 
Last’ovicka et al reported a CFSE-induced reduction in the proliferative capacity as a result of 
decreased viability of proliferating cells.89 Moreover, this study also reported a substantial 
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alteration to the expression of activation markers upon addition of CFSE to cells. However, 
while CFSE labelling of cells under some conditions can alter cell functionality, it is generally 
understood that in appropriate buffering conditions it has minimum cellular toxicity.90 
 
4.6 Project methodology: FTY720 method   
4.6.1 Rationale behind methodology  
To consolidate the data generated from the in vivo dual labelling experiment, the use of the 
immunomodulatory drug FTY720 was chosen as an alternative approach to test the same 
hypothesis that ILCs proliferate within the lungs following BCG vaccination. The effect of 
inhibiting ILC migration to the lungs from the lymph nodes and spleen indicates whether ILCs 
divide within the lungs, or whether they proliferate in secondary lymphoid tissue followed by 
trafficking to the lungs. If ILCs divide in secondary lymphoid tissue and then migrate to the 
lungs thereafter, a reduction in the proportion and number of proliferating ILCs would be 
expected. The efficacy of FTY720 in preventing lymphocyte egress in the murine model has 
been well established.  
 
4.6.2 Treatment of mice with FTY720   
FTY720 was administered to mice dissolved in drinking water rather than by oral gavage or by 
i.p. injection. Administration through drinking water is less invasive, minimises the handling 
of mice, and circumvents the requirement for time-consuming gavage or injection regimens, 
which would have been stressful for the mice. A recent study showed that administration of 
FTY720 in drinking water, rather than by daily i.p. injections, was equally effective in depleting 
CD4+ T cell and lymphocyte counts in the blood.91  Furthermore, this study reported no 
change in the volume of water consumption by mice upon supplementation with 2g/ml 
FTY720, suggesting the palatability of the drinking water was maintained.  
 
4.6.3 Potential limitations of this methodology  
One limitation of this experiment is that the data only show a snapshot of ILC proliferation 
that is occurring at precisely 4 weeks post-vaccination with BCG; the dynamicity of 
proliferation is not taken into account. Another potential limitation is that while lymphocytes 
and ILCs were significantly depleted in the blood following FTY720 treatment, a small degree 
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of egression from lymphoid tissue did still occur, which could have led some ILCs from the 
periphery entering the lungs.  
 
4.7 Corroboration of data by two distinct methods  
While there are limitations associated with both the in-vivo dual labelling experiment and the 
FTY720 experiment, one major strength of this project was that the use of these two different 
experimental approaches enabled the generation of robust data to support the hypothesis 
that ILCs proliferate locally within the lungs. The high degree of concordance among the 
findings from these two experiments suggest that the data are reliable and that the 
limitations of each method were unlikely to have affected the overall outcome.  
 
4.8 Future directions  
4.8.1 Repetition of the FTY720 experiment with the inclusion of temporal analyses  
It would be interesting to repeat the FTY720 experiment with the examination of ILC division 
occurring at different time points post BCG vaccination, to gauge the kinetics of ILC 
proliferation. The present study only analysed proliferation occurring at 4 weeks post-
vaccination; it would be useful to include earlier time points, such as 2 weeks post-
vaccination, as well as later time points such as 6 weeks post-vaccination, to gain insight into 
the longevity of ILC expansion.   
 
4.8.2 Investigate the biological relevance of ILCs in the lungs 
It would be valuable to examine the function of ILCs in mycobacterial-immunity to determine 
whether they are capable of protecting against TB disease, and therefore whether they would 
be a useful target for vaccine development.  Previous research conducted by the Kirman 
Laboratory discovered BCG-induced accumulation of ILC1s and ILC3s in the murine lung was 
associated with enhanced production of IFN-.64 It would be important to determine whether 
this cytokine production by these cells confers sufficient protection against disease. Another 
approach to explore the protection conferred by ILCs would be through the adoptive transfer 
of ILCs stimulated by BCG into naïve mice, followed by a challenge with BCG. However, it 
would be difficult to show that ILCs confer protection using this method, especially 
considering their low abundance.   
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Moreover, a knockout model with Il2rg-/- mice could be used to assess ILC-mediated 
protection to BCG, to see if these mice exhibit enhanced susceptibility to disease, and then 
whether protection can be restored by the adoptive transfer of ILCs into Il2rg-/- mice.  
 
4.8.3 Further research of ILC memory in the context of TB  
ILC memory in the context of TB has been identified within the NK cell subset and also within 
ILC2s. A sustained, robust memory response forms the basis of an effective vaccine. Further 
research is required to determine whether the memory response of ILCs exhibits sufficient 
strength to make these cells a viable target for vaccine development.   
 
4.9 Conclusion  
This research project used two distinct methods to confirm the hypothesis that ILCs 
proliferate locally within the lungs following vaccination with BCG, with ILCs accumulating in 
the lungs to the greatest extent at 4 weeks post-vaccination. These preliminary findings have 
laid the foundation and provided justification for the further research into the role and 
importance of ILCs in the immune response to TB, and potentially into the manipulation of 
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6 Appendices  
6.1 Appendix 1: Solutions and Buffers  
 
6.1.1 Phosphate Buffered Saline (PBS)  
One 9.6 g sachet of Dulbecco’s PBS powder (Gibco, Life Technologies, Grand Island, USA) was 
dissolved in 1L distilled water, filter sterilised, and stored at 4C.  
 
6.1.2 Fluorescence-activated cell sorting (FACS) Buffer  
PBS was aseptically combined with 0.05% v/v FCS and 2mM EDTA to produce FACS buffer, 
which was stored at 4C.  
 
6.1.3 Incomplete and Complete Iscove’s Modified Dulbecco’s Medium (iIMDM and cIMDM)  
One 500mL bottle of IMDM (Gibco, Life Technologies) was combined with 100U/ml 
penicillin/streptomycin (Gibco, Life technologies) and 55mM beta-2-mercaptoethanol (Gibco, 
Life Technologies) under aseptic conditions to produce incomplete IMDM (iIMDM). To create 
complete IMDM (iIMDM), 5% v/v FCS was combined with iIMDM. Media were stored at 4C.   
 
6.1.4 PBS-Tween 80  
Tween 80 (Sigma-Aldrich) was added to PBS to reach a concentration of 0.05% v/v under 
aseptic conditions. Media was filter-sterilised and stored at 4C.  
 
 
6.1.5 Lung Digest Media  
Media was prepared immediately prior to use. iIMDM was combined with 2.4ml/ml 
Collagenase Type I (Gibco, Life Technologies) and 0.12 mg/ml DNase I (Roche Diagnostics), 





6.1.6 Alsever’s Solution  
Alsever’s solution was produced by combining 20.5mg/ml dextrose, 4.2 mg/ml Sodium 
Chloride, and 8.0mg/ml Sodium Citrate.  
 
